Clinical situation of Venezuelan migrants living with HIV in a hospital in Lima, Peru

Genesis S Huerta-Vera1, Manuel A Amarista1, Fernando A Mejía1,2, Ana B Graña2, Elsa V Gonzalez-Lagos1,3 and Eduardo Gotuzzo1,2,3

Abstract
Due to a huge crisis extensive to health services many Venezuelan people living with HIV (PLWH) had migrated abroad, including Peru where favorable laws were in place until June 2019. We describe the health status and epidemiological trends of PLWH from Venezuela at an HIV program in Lima. We analyzed baseline and follow-up data of all Venezuelan PLWH enrolled in our HIV program from January 2017 to December 2019. A cross-sectional study in a subsample served to describe ARV adherence and context of migration. Between 2017-2019 our HIV Program registered 398 Venezuelan PLWH, representing 20% of the 2018 annual enrollments; numbers decreased since mid-2019. The median age was 30 years (IQR 26;37) and 90.5% were men. Between 2017 and 2019, the proportion with diagnosis in Peru increased from 14.3% to 60.9%; of AIDS stage at entry, from 8.8% to 27.2%. By December 2019, 182/250 (72.8%) were still in care, and 43 (10.8%) had not started ART. Viral suppression evaluated in 195, was achieved in 71.8%. From 2017 to 2019, migrant PLWH arrive without a clear clinical condition, with increasing diagnosis in Peru; the flow of migrant PLWH entering care diminished with less favorable laws. Viral suppression rates were suboptimal.

Keywords
Emigrants and immigrants, Peru, Latin America, Human migration, Venezuela, HIV infections

Date received: 18 January 2021; accepted: 17 May 2021

Introduction
Massive migrations challenge the public health systems of host countries, which need to prioritize disease control and provide responsive health services for the migrant population. By June 2019, amid an escalating socioeconomic crisis, at least four million people had departed from Venezuela1; half of their 650,000 asylum claims were presented to Peru.2 A Peruvian law enacted in 2017, and halted in June 2019, allowed that Venezuelan migrants could reside and work legally in the country for a year.3

The health system deterioration in Venezuela,4,5 extensive to health information systems,6 led to the reemergence of vaccine-preventable diseases and other infectious conditions, including HIV.7 In 2016, UNAIDS estimated a 24% increase in new HIV infections compared to those reported in 2010 in Venezuela, and a total of 120,000 people living with HIV (PLWH). Shortages of tests for diagnosis and laboratory monitoring and drug supplies for antiretroviral therapy (ART) and of health practitioners further affected the continuum of care5,8; by 2016, 59% of PLWH in Venezuela had access to ART and only 7% were virally suppressed.9 By 2019, approximately 8000 PLWH in Venezuela had migrated.10

At host countries, migrants encounter several challenges especially when trying to access health services.11 In an HIV cohort in Italy, migrants were at greater risk of viral and treatment failure than residents.12 According to a national survey directed to the Venezuelan population living in Peru, 93.3% lacked health insurance and half of them restrained from using health services.13 By December 2018,
approximately 1338 Venezuelan PLWH were receiving ART in Peru, 90% in the capital (Lima).10,14

In this study, we described the clinical and epidemiological characteristics of Venezuelan PLWH at the time of their entry to an HIV program in Lima and until 2 years afterward. In a subsample, we described adherence to ART, the reported reasons for nonadherence, and its impact on HIV outcomes.

Methods

Setting

Since 2008, most South American countries share a free transit policy with a waiver of visa requirements. In 2017, a Peruvian law allowed Venezuelan migrants to stay and work legally in Peru for a year; once it was reversed (June 2019), passports and permits were required for Venezuelan migrants who arrived at Peru.

ART and ART laboratory monitoring are provided free of charge to all PLWH enrolled in governmental-funded Peruvian HIV Programs. Until 2017, multidisciplinary appointments (medical, psychology, social services, and nurse evaluation) were mandatory to initiate ART. Between 2017 and 2018, a new Peruvian HIV guideline simplified such process, with only a mandatory physician appointment before ART initiation.15,16 Additional medical tests and appointments are out-of-pocket expenses for PLWH without social/health insurance. The latter can be granted to migrants who obtain a resident status or are considered a vulnerable population, although the process can take a couple of months.10,17

The HIV program at our study center, in Lima, provides clinical care to the largest HIV cohort in Peru. When PLWH are enrolled in the HIV program, nurses fill out a structured questionnaire regarding past medical history, date of HIV diagnosis, and previous use of ART; a medical questionnaire filled out by infectious diseases specialists lists the clinical diagnoses at entry. Whenever available, the physicians attach documents from previous medical reports. Nurses register the dates of visit and the ART regimen at each ART pickup appointment, as well as CD4+ count and viral load results. As part of the standard of care, nurses make efforts to contact patients identified as ART abandonment or those who became lost to follow-up before ART start by phone call or home visits, aiming to facilitate their return to care. PLWH in need of admission are hospitalized at the Infectious Disease Unit of the study center. At discharge, a physician fills out a structured form that summarizes the period of hospitalization, diagnoses, and vital status.

The information generated by all these procedures is entered into an anonymized database whose use and data management is supported by the Caribbean, Central and South America network for HIV Epidemiology.18

Study design and study population

For the secondary data analysis, we considered all HIV program files and hospital discharge forms of patients aged 18 or more with Venezuelan nationality that entered the HIV program at the study center from January 2017 to December 2019.

For the cross-sectional component of this study, we contacted PLWH who attended the HIV Program between September 2019 to December 2019 for ART pickup or ART restart.

Study procedures

For the secondary data analysis, we used a digital data collection form to retrieve the epidemiological (age, sex, sexual orientation, and level of education), clinical (baseline CD4+ count and viral load, HIV/TB coinfection, and previous ART treatment), ART (drug combination and ART changes), admissions (hospitalizations and diagnoses), and HIV outcomes (viral suppression, ART abandonment, and death) information. We contrasted these data with the datasets from the routine HIV program database. Additional data quality control was done in a random selection of 50% of the files; discrepancies were solved by review of the original forms. Information about previous HIV diagnosis and ARV treatment was obtained by a nurse or physician and registered in their respective questionnaire including the medical report from Venezuela when available.

For the cross-sectional component, the nursing HIV program staff contacted eligible participants during either their visits to the HIV program or via phone calls or home visits because of abandonment or lost to follow-up. PLWH who provided informed consent, responded to the study questionnaire. The questionnaire inquired about HIV clinical information in Venezuela, the itinerary to access health care in Peru, the SMAQ questionnaire19 for adherence, and information on the reasons for abandonment and nonadherence. This information was entered into a study database.

Variable definitions

We defined baseline CD4+ count and viral load as the first measure taken in Peru; TB coinfection by the initiation of TB treatment; and for those who had started ART, ART abandonment was the lack of ART pickup visits for more than 90 consecutive days. We defined viral suppression as ≤ 40 copies/ml and virologic failure as > 200 copies/ml; in both cases, we considered the last viral load test performed between 3 and 9 months after ART initiation at our study center. Thus, these outcomes are presented for PLWH with at least 3 months of follow-up.

We defined ART nonadherence either by (i) a positive response in any of the questions of the SMAQ questionnaire; or the loss of (ii) more than two ART doses during the
last week; or (iii) for more than two consecutive days in the last 3 months.19

**Statistical analysis**

For quality control, we carried double digitation for 20% of the data to check for typing or content errors. We calculated mean and standard deviation for quantitative variables with normal distribution and median and interquartile range for those with nonparametric distribution. For categorical variables, we reported absolute and relative frequencies. Baseline and follow-up characteristics were analyzed by the year of enrollment in the HIV Program to determine trends over time of the clinical conditions at entry. We used STATA 15 (Stata Statistical Software; Stata Corporation, College Station, TX, licensed by Universidad Peruana Cayetano Heredia) for data management and statistical analyses.

**Ethics**

The study protocol, including the informed consent for the cross-sectional component, was approved by the Institutional Review Boards of the Universidad Peruana Cayetano Heredia and the Hospital Cayetano Heredia.

**Results**

From January 2017 to December 2019, the HIV program at our center registered 398 Venezuelan PLWH (Figure 1); this represented 4.4% of new enrollments in 2017, 20% in 2018, and 18.7% in 2019. The peak of new enrollments of PLWH migrating from Venezuela to Peru was observed in the second trimester of 2018 (65 new enrollments), and it decreased to 38 in 2019, after more restricted Peruvian border control laws came into force (Figure 2).

![Figure 1. Patients flowchart. *Reasons for follow-up exclusion: 19 started after 30 November 2019; 69 had no information of antiretroviral therapy pick up. PLWH: People living with HIV; ART: antiretroviral therapy; VEN: Venezuela; PER: Peru; HCH: Hospital Cayetano Heredia.](image1)

![Figure 2. Number of enrollment of HIV positive Venezuelan patients in HCH HIV program by trimesters. †In June 2019 new border-control laws were enforced for Venezuelen immigrants, adding requirements to enter the country.](image2)
The median age of Venezuelan PLWH enrolled at our center was 30 years (IQR 26; 37); 90.5% were male. By time of enrollment, seven out of 38 women were pregnant and two in postpartum period. Most of our study population had higher education (71.3%), were single (77.4%), and identified themselves as men who have sex with men (52.9%). One-third of the study population was diagnosed with HIV infection in Peru and 19% had a CD4+ count below 200 cells/mm³. Table 1 presents baseline characteristics of our study population.

Throughout the study period, the proportion of migrants enrolled in our HIV program with a previous HIV diagnosis in Venezuela decreased from 85.7% (2017) to 39.8% (2019); the median baseline CD4+ count also decreased: from 488 [IQR 294–633] in 2017 to 346 [IQR 161–588] in 2019. In 2017, the majority of patients were on viral suppression at baseline (63%) in comparison with 11.2% in 2019. The comparison of clinical characteristics by year of enrollment is summarized in Table 2. Overall, the group diagnosed in Venezuela (251) was less compromised at entry in our HIV program, with higher median baseline CD4+, lower percentage of AIDS cases, and higher frequency of ART start (250, 91.6%) (Table 3). In the cross-sectional study (n = 137), the median time between the arrival to Peru to the first encounter with our hospital was 121 days [IQR 24; 315] for all participants and 52.5 days [IQR 7; 109] for the participants with HIV diagnosed in Venezuela.

### Follow-up information

The median time since the enrollment to the HIV program until the initiation of ART was 22 days (IQR 14; 43); it was 24.5 days (IQR 16; 47) for those diagnosed in Peru and 21 days (IQR 10; 38) for those diagnosed in Venezuela. Among PLWH whose baseline CD4+ count was below 50 cells/mm³, the median time to ART initiation was 19.5 days (IQR 14.5; 30). Out of 191 with information on the last ART combination used in Venezuela, 120 (62.8%) maintained such ART combination in our HIV program, with TDF/FTC/EFV as the most frequent (71, 59.2%).

Until the end of follow-up, ART combinations prescribed at our HIV program were modified in 18 PLWH due to adverse drug reactions (8 cases) predominantly cutaneous; virologic failure (4 cases); and pregnancy, renal disease, and TB treatment (2 cases per each category). After a moderate or severe adverse drug reaction to 2NRTIs + NNRTI, the usual treatment modification was 2NRTIs + PI.

### Table 1. Baseline characteristics (n = 398).

| Characteristic                  | N (%); median (IQR) |
|--------------------------------|---------------------|
| Male                           | 360 (90.5)          |
| Age (years)                    | 30 (26; 37)         |
| Level of education             |                     |
| Primary school                 | 18 (4.5)            |
| Secondary school               | 96 (24.2)           |
| Higher education               | 283 (71.3)          |
| Marital status                 |                     |
| Married or cohabitant          | 82 (20.6)           |
| Divorced or separated          | 8 (2)               |
| Single                         | 308 (77.4)          |
| Sexual orientation             |                     |
| Bisexual                       | 104 (26.2)          |
| Heterosexual                   | 83 (20.9)           |
| Homosexual                     | 210 (52.9)          |
| Place of diagnosis             |                     |
| Venezuela                      | 251 (63.1)          |
| Peru                           | 147 (36.9)          |
| Previous ART in Venezuela      | 235 (93.6)          |
| First CD4+ count (cell/ml)     | 395.5 (233; 612)    |
| >500                           | 132 (35.7)          |
| 350–499                        | 78 (21.1)           |
| 200–349                        | 90 (24.3)           |
| 50–199                         | 45 (12.1)           |
| <50                           | 25 (6.8)            |
| First viral load (copies/ml)   | 20500 (75.1; 143000) |
| <40                            | 89 (23.1)           |
| 40–500                         | 31 (8)              |
| 500–10000                      | 43 (11.1)           |
| >100000                       | 223 (57.8)          |
| HIV/TB coinfection            | 10 (2.5)            |
| Pregnancy (n = 38)             | 9 (23.7)            |
| Year enrolled in HIV program   |                     |
| 2017                           | 35 (8.8)            |
| 2018                           | 202 (50.7)          |
| 2019                           | 161 (40.5)          |

*Variables can add up to less than 398 due to missing data.

### Table 2. Clinical characteristic by year of enrollment.

| Characteristic                          | 2017 (n = 35)      | 2018 (n = 202) | 2019 (n = 161) |
|----------------------------------------|--------------------|----------------|----------------|
| CD4+ count                             | 488 (294; 633)     | 407 (259; 617) | 346 (161; 588) |
| AIDS                                   | 3 (8.8)            | 27 (14.3)      | 40 (27.2)      |
| Viral suppression at start of ART at study center* | 20 (63)           | 54 (26.4)      | 15 (11.2)      |
| HIV diagnosis in Venezuela             | 30 (85.7)          | 157 (77.7)     | 64 (39.8)      |

*Variables with missing data (>5%).
According to the cross-sectional study \((n = 137)\), 67.2% showed nonadherence to ART; the main reported reasons were forgetfulness to take pills (22.6%) and conflicting schedules (21.9%).

Of those who initiated ART during the study period, 250 were included in our final analysis for retention in care: 182 (72.8%) were considered in care and 68 (27.2%) as abandonment, which included 12 PLWVH (17.6%) who had already left Peru. Out of 195 (61.0%) with a viral load measure between 3 and 9 months, 140 (71.8%) achieved viral suppression and 29 (14.9%) had virologic failure. PLWH diagnosed in Venezuela had higher percentage of virologic failure despite better baseline clinical characteristics (Table 3).

In our study population, we identified 22 hospital admissions: 13 occurred in PLWH who had not yet started ART and nine occurred after ART start. The most frequent diagnoses were tuberculosis (7 PLWH), cytomegalovirus (3 PLWH), and histoplasmosis (2 PLWH).

By December 2019, 43 (10.8%) Venezuelan PLWH had not started ART at the study center (Figure 1): 16 were still in the process to start ART at the study center, given that economical and time limitations had hampered the completion of the laboratory or medical appointments; 12 had transferred their HIV care to an other health establishment in Peru. We identified five deaths: three occurred within the first month after enrollment in PWLH whose baseline CD4+ counts were below 200 cell/ml and one corresponded to someone who had not started ART. Causes of death were tuberculous meningitis (1 PLWH), Pneumocystis jiroveci pneumonia (PJP) (1 PLWH), Kaposi’s sarcoma (1 PLWH), and unknown (2 PLWH).

### Discussion

Conducted at the largest HIV program in Peru, this study reports, first, a sustained increase in the number of Venezuelan PLWH attended by such program, which reaches a peak of 20% of new enrollments in 2018 but ceased since mid-2019, once modifications in Peruvian law restricted such migration. A second major finding is the increasing proportions in time of Venezuelan migrants who entered into care in AIDS stage and with HIV diagnosed in Peru. The profile of the initial migrants who entered the HIV Program were men who have sex with men diagnosed in Venezuela, without AIDS, and with a high proportion of viral suppression at enrollment. As our results showed, the number of PLWH whose HIV diagnosis was made in Peru increased in later periods in parallel with the cases in AIDS stage at diagnosis. Compared to native citizens, migrant populations tend to present with advanced HIV disease at their initial healthcare encounter at host countries.12,20,21

Our findings also are consistent with an initial “healthy migrant effect”22: the initial migrants usually have better conditions than those that migrate later, especially those virally suppressed at baseline. Interestingly, despite baseline characteristics, migrant PLWH diagnosed in Peru had better results for viral suppression (74.2% vs 70.7%) and virologic failure (6.9% vs 16.5%) compared with those diagnosed

### Table 3. Clinical characteristic by place of diagnosis and year of enrollment.

| Characteristic                       | Venezuela (n = 251) | Peru (n = 147) |
|--------------------------------------|--------------------|----------------|
|                                      | N (%); median (IQR)| N (%); median (IQR) |
| Baseline                             |                    |                |
| Age                                  | 31.7 (27.4–37.8)   | 31.0 (22.5–32.3) |
| Female                               | 4 (13.3)           | 0              |
| CD4+ counta                          | 531 (323–673)      | 305.5 (273.5–354.5) |
| AIDS stagea                          | 3 (10)             | 0              |
| Started ART                          | 28 (93.3)          | 5 (100)        |
| Follow-up                            | Venezuela (n = 133)| Peru (n = 62)  |
| Achieved viral suppressiona          | 14 (87.5)          | 3 (100)        |
| Virologic failurea                   | 0                  | 0              |

*Variables with missing data.
in Venezuela, which might respond to a differential risk of ART interruptions and viral resistance by time of enrollment.

We should remark that the increasing trend of enrollments in our HIV program started to diminish in late 2018 and was clearly reduced in 2019, after the imposition of new border control laws, which also increased documentation requirements. Although our study did not directly assess the implications of those border control laws, our findings suggest their potential effect on limiting access to HIV care, a situation that implies a higher risk of HIV-related complications. Relatedly, an increase of morbidity of various diseases has been reported in the Colombia and Brazil borders.

Ten percent of our study population had not started ART until the end of follow-up, mainly restrained by economic and time reasons; in addition, only 61% had viral load measures to assess viral suppression, without differences comparing PLWH diagnosed in Peru and Venezuela. In a situation well described which ultimately affects HIV care, direct and indirect costs (medical appointment, laboratory tests, transport, and day of work missed) could be unaffordable for migrant PLWH, even though the HIV program provides free ART drugs and ART laboratory monitoring. Poverty, social support, mental health problems, and legal status need to be addressed as major barriers for the continuity of HIV care of migrants.

Women are particularly vulnerable to the violence and disparities of migration processes. According to a local study, 17.8% of Venezuelan women in Peru reported being victims of harassment and 2.9% knew a victim of sexual assault. In our study, women represented a minority (9.5%) throughout the whole period, but the percentage of women in 2019 exceeded that of the two previous years combined. According to the International Organization for Migration, from July to December 2019, the percentage of Venezuelan women crossing the Peruvian border was, for the first time, slightly higher than men. Given that migrants might face a high-risk environment for HIV transmission, determined by the confluence of poverty, violence, and at-risk sexual behaviors, it is important to understand if sexual violence and/or sexual work is driving migration in Peru became noticeable, migrants might face a high-risk environment for HIV infection, from July to December 2019, the percentage of Venezuelan women crossing the border was slightly higher than men. Given that migrants might face a high-risk environment for HIV transmission, determined by the confluence of poverty, violence, and at-risk sexual behaviors, it is important to understand if sexual violence and/or sexual work is driving migrants to seek safer places.

The barriers for obtaining a legal status contribute to informal and “under the table” workers’ status, limiting healthcare access. Moreover, once the Venezuelan migration in Peru became noticeable, migrants might have encountered an increasing wave of xenophobia and discrimination. Thus, beyond the burden of HIV stigma, Venezuelan PLWH might have faced xenophobia and negative context reception, which directly affect their mental health and hamper linkage to health services and retention in care. In this context, it is possible that, through a snowball effect, migrant PLWH could share information about certain HIV health services as “safer places” for peers.

Acknowledgements
We thank The Caribbean, Central, and South America network for HIV epidemiology (CCASAnet) information for providing access to their local database.

Author contributions
Genesis S Huerta-Vera completed the data collection, formal analysis, and did the original draft preparation. Manuel A Amarista was responsible for conceptualization and methodology.
A Mejía was responsible for conceptualization and supervision. Ana B Graña was responsible for the project administration, resources, and conceptualization. Elsa V González-Lagos supervised the study and did the review and editing of the manuscript. Eduardo Gotuzzo was responsible for conceptualization, methodology, funding acquisition, study supervision, manuscript review, and editing.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The financial contribution of UNAIDS towards this activity is gratefully acknowledged. However, its content and ideas expressed therein do not necessarily reflect the views and opinions of UNAIDS or engage the responsibility of UNAIDS; research reported in this publication was supported by the Fogarty International Center and National Institute of Child Health & Human Development of the National Institutes of Health under Award Number D43 TW009763. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclaimer
This study was presented in the virtual poster exhibition at the 23rd International AIDS Conference (AIDS 2020: Virtual), held on 6–10 July 2020.

ORCID iD
Genesis S Huerta-Vera https://orcid.org/0000-0002-5782-2940

References
1. United Nations. Four million have now fled Venezuela, UN ramps up aid to children who remain [Internet]. UN News. [cited 16 February 2020]. Available from: https://news.un.org/en/story/2019/06/1040001 (2019).
2. United Nations High Commissioner for Refugees (UNHCR). Venezuela Situation [Internet]. [cited 16 February 2020]. Available from: https://data2.unhcr.org/en/situations/venusit
3. Ministerio del Interior. Aplicación de visa a nacionales venezolanos. [cited 10 November 2020]. Available from: https://www.gob.pe/institucion/tre/ree/noticias/29204-aplicacion-de-visa-a-nacionales-venezolanos (2019).
4. Fraser B and Willer H. Venezuela: aid needed to ease health crisis. The Lancet 2016; 388(10048): 947–949.
5. Lancet T. The collapse of the Venezuelan health system. The Lancet 2018; 391(10128): 1331.
6. Grillet ME, Hernández-Villena JV, Llewellyn MS, et al. Venezuela’s humanitarian crisis, resurgence of vector-borne diseases, and implications for spillover in the region. Lancet Infect Dis 2019; 19(5): e149–e161.
7. Tutte AR, Thomas-Bachli A, Acosta H, et al. Infectious disease implications of large-scale migration of Venezuelan nationals. J Trav Med 2018; 25(1): 077.
8. Daniels JP. Venezuela’s economic crisis hampers HIV/AIDS treatment. The Lancet 2017; 389(10074): 1088–1089.
9. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2017 [Internet]. [cited 23 April 2021]. Available from: https://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf
10. Silva-Santisteban A. Diagnóstico rápido: Situación de los migrantes venezolanos con VIH en el Perú. Informe ONUSIDA. [Internet]. Available from: http://onusidalac.org/1/images/2018/diagnostico-rapido-migrantes-con-vih-peru.pdf (2019).
11. Winters M, Rechel B, de Jong L, et al. A systematic review on the use of healthcare services by undocumented migrants in Europe. BMC Health Serv Res 2018; 18(1): 30.
12. Saracino A, Lorenzini P, Lo Caputo S, et al. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2016; 22(3): 288.
13. Hernández-Vásquez A, Vargas-Fernández R, Rojas-Roque C, et al. Factores asociados a la no utilización de servicios de salud en inmigrantes venezolanos en Perú. Rev Peru Med Exp Salud Pública 2019; 36(4): 583–591.
14. Rebello-Ponietsky K, Munayco CV and Mezones-Holguín E. Migration crisis in Venezuela: impact on HIV in Peru. J Trav Med 2019; 26(2): 155.
15. Norma MINSA. Técnica de Salud de Atención Integral del Adulto con Infección por El Virus De La Inmunodeficiencia Humana (VIH) [Internet]. NTS N° 097-MINSA/DGSP 2014, Available from: http://www.digemid.minsa.gob.pe/UpLoad/Uploaded/PDF/Normatividad/2014/RM_962-2014.pdf
16. Norma MINSA. Técnica de Salud de Atención Integral del Adulto con Infección por El Virus De La Inmunodeficiencia Humana (VIH) [Internet]. NTS N° 097-MINSA/2018/DGIESP April, 2018, Available from: http://bvs.minsa.gob.pe/local/MINSA/4479.pdf
17. Legislativo Poder. Reglamento del Decreto Legislativo N° 1350, Decreto Legislativo de Migraciones [Internet]. no 007-2017-in, Available from: http://busquedas.elperuano.pe/normaslegales/reglamento-del-decreto-legislativo-n-1350-decreto-legislat-anexo-ds-n-007-2017-in-1502810-4/
18. McGowan CC, Cahn P, Gotuzzo E, et al. Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol 2007; 36(5): 969–976.
19. Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS Lond Engl 2002; 16(4): 605–613.
20. Doocy S, Page KR, Hoz F de la, et al. Venezuelan Migration and the Border Health Crisis in Colombia and Brazil. J Migr Hum Secur 2019; 7(3): 233150241986013.
21. Monge S, Alejos B, Dronda F, et al. Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain. HIV Med 2013; 14(5): 273–283.
22. Razum O, Zeeb H and Rohrmann S. The ‘healthy migrant effect’–not merely a fallacy of inaccurate denominator figures. Int J Epidemiol 2000; 29(1): 191–192.
23. International Organization of Migration (IOM). Perú — Flujo de Migración Venezolana, Ronda 7 (Febrero 2020) | DTM [Internet]. 2020 Feb [cited 11 April 2020], Available from: https://dtm.iom.int/reports/per%C3%BA-%E2%80%94-flujo-de-migracion%CF%80venezolana-ronda-7%C2%A0febrero-2020

24. Marukutira T, Yin D, Cressman L, et al. Clinical outcomes of a cohort of migrants and citizens living with human immunodeficiency virus in Botswana: implications for Joint United Nation Program on HIV and AIDS 90-90-90 targets. Medicine (Baltimore) 2019; 98(23): e15994.

25. Rios Casas F, Ryan D, Perez G, et al. “Se vale llorar y se vale reír”: Latina immigrants’ coping strategies for maintaining mental health in the face of immigration-related stressors. J Racial Ethn Health Disparities 2020; 7(5):937–948.

26. Mendoza W and Miranda JJ. La inmigración venezolana en el Perú: desafíos y oportunidades desde la perspectiva de la salud. Rev Peru Med Exp Salud Pública 2019; 36(3): 497–503.

27. International Organization of Migration (IOM) Perú. DTM Ronda 4 - Monitoreo de flujo de migración venezolana en el Perú [Internet]. UNHCR Operational Data Portal (ODP). [cited 11 November 2020], Available from: https://data2.unhcr.org/en/documents/details/68475 (2018).

28. Naicker N, Pega F, Rees D, et al. Health services use and health outcomes among informal economy workers compared with formal economy workers: a systematic review and meta-analysis. Int J Environ Res Public Health 2021; 18(6): 3189.

29. Hargreaves S, Rustage K, Nellums LB, et al. Occupational health outcomes among international migrant workers: a systematic review and meta-analysis. Lancet Glob Health 2019; 7(7): e872–e882.

30. Feline Freier L and Pérez LM. Nationality-Based Criminalisation of South-South Migration: the Experience of Venezuelan Forced Migrants in Peru. 2021; 133: 113–133.

31. Instituto de Opinión Pública Pontificia Universidad Católica del Perú. Cambios en las Actitudes hacia los Inmigrantes Venezolanos en Lima-Callao 2018-2019 [Internet]. Pontificia Universidad Catolica del Perú; February 2020. [cited 8 May 2021], Available from: http://repositorio.pucp.edu.pe/index/handle/123456789/169459

32. Schwartz SJ, Unger JB, Lorenzo-Blanco EI, et al. Perceived context of reception among recent Hispanic immigrants: conceptualization, instrument development, and preliminary validation. Cultur Divers Ethnic Minor Psychol 2014; 20(1): 1–15.

33. Schwartz SJ, Salas-Wright CP, Pérez-Gómez A, et al. Cultural stress and psychological symptoms in recent Venezuelan immigrants to the United States and Colombia. Int J Intercult Relations 2018; 67: 25–34.

34. Mougenot B, Amaya E, Mezones-Holguin E, et al. Immigration, perceived discrimination and mental health: evidence from Venezuelan population living in Peru. Glob Health 2021; 17(1): 1–9.

35. OECD. Monitoring Health System Performance in Peru: Data and Statistics [Internet]. OECD; 2017 [cited 2021 May 8]. (OECD Reviews of Health Systems), Available from: https://www.oecd-ilibrary.org/social-issues-migration-health/monitoring-health-system-performance-in-peru_9789264282988-en